Erratum: Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis ( Proc. Natl. Acad. Sci. U.S.A. (2015) 112 (E3402-E3411) DOI: 10.1073/pnas.1420005112);Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 26, 2015, Pages E3402-E3411

  Eisinger Mathason, T S Karin ^a   Mucaj, Vera ^a   Biju, Kevin M ^a   Nakazawa, Michael S ^a   Gohil, Mercy ^a   Cash, Timothy P ^a   Yoon, Sam S ^b   Skuli, Nicolas ^c   Park, Kyung Min ^d   Gerecht, Sharon ^d   Simon, M Celeste ^a,e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d Johns Hopkins University   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

FOXM1; Hippo; Sarcoma; YAP

Indexed keywords

HIPPO PROTEIN; MESSENGER RNA; PROTEIN; TEAD1 PROTEIN; THIOSTREPTON; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; TRANSCRIPTION FACTOR YAP; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; HIPPO PROTEIN, HUMAN; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CHROMATIN; COMPLEX FORMATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG TARGETING; EMBRYONAL RHABDOMYOSARCOMA; G2 PHASE CELL CYCLE CHECKPOINT; GENE CONTROL; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; TUMOR VOLUME; METABOLISM; PATHOLOGY; PHYSIOLOGY; SARCOMA; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; PHOSPHOPROTEINS; PROTEIN-SERINE-THREONINE KINASES; SARCOMA;

EID: 84937962607     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.2321173121     Document Type: Erratum

References (51)

1. Taylor BS, et al. (2011) Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer 11(8):541-557.
2. Lauer S, Gardner JM (2013) Soft tissue sarcomas - new approaches to diagnosis and classification. Curr Probl Cancer 37(2):45-61.
3. Kelleher FC, Viterbo A (2013) Histologic and genetic advances in refining the diagnosis of "undifferentiated pleomorphic sarcoma". Cancers (Basel) 5(1):218-233.
4. Eisinger-Mathason TS, et al. (2013) Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. Cancer Discov 3(10):1190-1205.
5. Linehan DC, Lewis JJ, Leung D, Brennan MF (2000) Influence of biologic factors and anatomic site in completely resected liposarcoma. J Clin Oncol 18(8):1637-1643.
6. Pan D (2010) The hippo signaling pathway in development and cancer. Dev Cell 19(4):491-505.
7. Zhang N, et al. (2010) The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 19(1):27-38.
8. Harvey KF, Zhang X, Thomas DM (2013) The Hippo pathway and human cancer. Nat Rev Cancer 13(4):246-257.
9. Sekido Y, et al. (1995) Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 55(6):1227-1231.
10. Mizuno T, et al. (2012) YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. Oncogene 31(49):5117-5122.
11. Yoo NJ, Park SW, Lee SH (2012) Mutational analysis of tumour suppressor gene NF2 in common solid cancers and acute leukaemias. Pathology 44(1):29-32.
12. Je EM, Choi YJ, Chung YJ, Yoo NJ, Lee SH (2015) TEAD2, a Hippo pathway gene, is somatically mutated in gastric and colorectal cancers with high microsatellite instability. Acta Pathol Microbiol Immunol Scand 123(4):359-360.
13. Hélias-Rodzewicz Z, et al. (2010) YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas. Genes Chromosomes Cancer 49(12):1161-1171.
14. Seidel C, et al. (2007) Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog 46(10):865-871.
15. Kim JE, Finlay GJ, Baguley BC (2013) The role of the hippo pathway in melanocytes and melanoma. Front Oncol 3:123.
16. Zhao B, Tumaneng K, Guan KL (2011) The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol 13(8):877-883.
17. Wierstra I (2013) FOXM1 (Forkhead box M1) in tumorigenesis: Overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. Adv Cancer Res 119:191-419.
18. Kalinichenko VV, et al. (2004) Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev 18(7):830-850.
19. Pandit B, Halasi M, Gartel AL (2009) p53 negatively regulates expression of FoxM1. Cell Cycle 8(20):3425-3427.
20. Wierstra I, Alves J (2006) Transcription factor FOXM1c is repressed by RB and activated by cyclin D1/Cdk4. Biol Chem 387(7):949-962.
21. Halasi M, Gartel AL (2013) FOX(M1) news - it is cancer. Mol Cancer Ther 12(3):245-254.
22. Kirsch DG, et al. (2007) A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med 13(8):992-997.
23. Crose LE, et al. (2014) Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression. J Clin Invest 124(1):285-296.
24. Tremblay AM, et al. (2014) The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. Cancer Cell 26(2):273-287.
25. Mito JK, et al. (2009) Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS ONE 4(11):e8075.
26. Liu-Chittenden Y, et al. (2012) Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev 26(12):1300-1305.
27. Detwiller KY, et al. (2005) Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res 65(13):5881-5889.
28. Nakayama R, et al. (2007) Gene expression analysis of soft tissue sarcomas: Characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol 20(7):749-759.
29. Zhao B, et al. (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22(14):1962-1971.
30. Mossing MC, Record MT, Jr (1986) Upstream operators enhance repression of the lac promoter. Science 233(4766):889-892.
31. Bhat UG, Halasi M, Gartel AL (2009) FoxM1 is a general target for proteasome inhibitors. PLoS ONE 4(8):e6593.
32. Halasi M, Gartel AL (2009) A novel mode of FoxM1 regulation: Positive auto-regulatory loop. Cell Cycle 8(12):1966-1967.
33. Wang M, Gartel AL (2011) Micelle-encapsulated thiostrepton as an effective nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human xenografts. Mol Cancer Ther 10(12):2287-2297.
34. Parham DM, Ellison DA (2006) Rhabdomyosarcomas in adults and children: An update. Arch Pathol Lab Med 130(10):1454-1465.
35. Zhang W, et al. (2014) Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal 7(324):ra42.
36. Azzolin L, et al. (2014) YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell 158(1):157-170.
37. Vijayakumar S, et al. (2011) High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A. Cancer Cell 19(5):601-612.
38. Sasaki K, Hitora T, Nakamura O, Kono R, Yamamoto T (2011) The role of MAPK pathway in bone and soft tissue tumors. Anticancer Res 31(2):549-553.
39. Gusarova GA, et al. (2007) A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J Clin Invest 117(1):99-111.
40. Michels S, Schmidt-Erfurth U (2001) Photodynamic therapy with verteporfin: A new treatment in ophthalmology. Semin Ophthalmol 16(4):201-206.
41. Lamar JM, et al. (2012) The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci USA 109(37):E2441-E2450.
42. Lok GT, et al. (2011) Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells. PLoS ONE 6(8):e23790.
43. Kalinichenko VV, et al. (2002) Haploinsufficiency of the mouse Forkhead Box f1 gene causes defects in gall bladder development. JBiolChem277(14):12369-12374.
44. Massuda ES, et al. (1997) Regulated expression of the diphtheria toxin A chain by a tumor-specific chimeric transcription factor results in selective toxicity for alveolar rhabdomyosarcoma cells. Proc Natl Acad Sci USA 94(26):14701-14706.
45. Peng T, et al. (2011) An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Lab Invest 91(3):392-403.
46. Roessler S, et al. (2010) A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 70(24):10202-10212.
47. Hou J, et al. (2010) Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS ONE 5(4):e10312.
48. Mahoney WM, Jr, Hong JH, Yaffe MB, Farrance IK (2005) The transcriptional coactivator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members. Biochem J 388(Pt 1):217-225.
49. Jiang SW, Desai D, Khan S, Eberhardt NL (2000) Cooperative binding of TEF-1 to repeated GGAATG-related consensus elements with restricted spatial separation and orientation. DNA Cell Biol 19(8):507-514.
50. Chen X, et al. (2013) The forkhead transcription factor FOXM1 controls cell cycle-dependent gene expression through an atypical chromatin binding mechanism. Mol Cell Biol 33(2):227-236.
51. Sengupta A, Kalinichenko VV, Yutzey KE (2013) FoxO1 and FoxM1 transcription factors have antagonistic functions in neonatal cardiomyocyte cell-cycle withdrawal and IGF1 gene regulation. Circ Res 112(2):267-277.